Celgene, Sanofi eye autoimmune disease | Chemical & Engineering News
Volume 95 Issue 3 | p. 11 | Concentrates
Issue Date: January 16, 2017

Celgene, Sanofi eye autoimmune disease

Department: Business
Keywords: biotechnology, autoimmune disease, Celgene, Sanofi

At the start of the JPMorgan Healthcare Conference in San Francisco last week (see page 9), Celgene and Sanofi both announced partnerships in autoimmune disease. Celgene is paying privately-held Anokion $45 million up front for access to its antigen engineering technology in a deal that includes an option to purchase the biotech firm. Sanofi, meanwhile, will pay an undisclosed sum for rights to ImmuNext’s INX-021, a CD40L antibody in preclinical development with potential to treat a swath of autoimmune diseases. Milestone payments could reach $500 million.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment